Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.
about
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesStructure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡Role of a Putative gp41 Dimerization Domain in Human Immunodeficiency Virus Type 1 Membrane FusionMolecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanismSpecific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule.Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitorAn antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationThe conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entryCD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5Enfuvirtide: a novel agent for the treatment of HIV-1 infection.Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?A dual-functional paramyxovirus F protein regulatory switch segment: activation and membrane fusionThe long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibilityCross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsBinding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41.Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors.Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.Two domains that control prefusion stability and transport competence of the measles virus fusion protein.A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.Kinetic dependence to HIV-1 entry inhibition.Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.A novel view of modelling interactions between synthetic and biological polymers via docking.Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities.
P2860
Q27485578-83B13278-A8AB-4AB3-81BA-2A854145E72AQ27653846-233704B7-D8EF-424A-97E1-46BE112916F7Q27657871-77018450-7289-4F4B-9AB7-7E1007C224AEQ28544927-5784FF90-0572-4C29-8EEE-663F04C07B21Q31035724-5DE4875A-AE2F-4C25-ACF1-A1E382FCE4FCQ33724295-E4C26E4E-7790-4CDE-9088-CC95B0CE722AQ33780643-70BD4885-B450-4089-8961-05DD4EBC9146Q33877501-07A1ACA7-A36D-4DBB-92A3-ED05B81E2B92Q33946158-10E68BA6-493D-4758-9913-414293ECD5B3Q34412839-8008DB1A-A448-4B45-B33F-53B04CB1D93FQ34462299-C0A2830E-3B98-4422-9616-C7023B831C03Q35547218-6B31BB9B-AAD9-48F7-8E47-FA7A97513FB5Q35857279-2B17A495-D1D4-4D0F-B674-2EC8F119DA21Q35898024-42D904D3-1BEF-49CF-8C0D-1E4330D4E074Q36324552-DD7E939A-12DA-4B22-BEB2-6FCEC7CF12C6Q36509423-A9E328A5-A519-463F-8C16-83957FF30ABEQ36559735-00E5D48C-5545-4ECB-B479-8E742E2EA18BQ36747750-9466BB07-BD1E-4B1F-A8E5-7B6FEBF69A5EQ36945152-4BA3E8D7-92B3-4DB1-BF0A-8ABBD1DA46CBQ36954635-10C1CB32-0156-4A88-BED1-29A7278BE3DAQ37422890-DD97ACEB-B016-4757-BCAC-86FAA28D642AQ39766027-F2AC5F8D-02DD-4C80-88C6-FB9542064F90Q39943795-B8B62511-AB82-497A-BB54-228C0A6C2E5AQ40410440-A989286C-D7CF-46BE-B406-C9144121C4EDQ40721814-BB484199-7D33-4F42-BE17-5FD61B4B413DQ41955046-ED5FAD0F-AF8B-4FC2-8732-F408E34B015AQ42709844-8B8CAD71-91F6-4684-A572-241E1026E365Q42850455-ADC2CB17-30E5-4D6E-BAFE-F64031483600Q43627216-36D67200-5EFB-4BAC-AEDF-55A822871697Q43932246-E9CD0966-889B-48FC-B462-8057F66221BBQ44141083-1CFC355D-F105-463B-8C1C-415EC4B13710Q44536459-ABA8C359-3F11-405A-A756-9D4632E3D0C3Q44635089-6A80D89D-1E48-43CA-B6F3-24D88425EBEAQ46779182-D9E82FC1-39B8-4E70-A98E-39042D36C499
P2860
Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genetic evidence that interhel ...... in to the fusion-active state.
@ast
Genetic evidence that interhel ...... in to the fusion-active state.
@en
Genetic evidence that interhel ...... in to the fusion-active state.
@nl
type
label
Genetic evidence that interhel ...... in to the fusion-active state.
@ast
Genetic evidence that interhel ...... in to the fusion-active state.
@en
Genetic evidence that interhel ...... in to the fusion-active state.
@nl
prefLabel
Genetic evidence that interhel ...... in to the fusion-active state.
@ast
Genetic evidence that interhel ...... in to the fusion-active state.
@en
Genetic evidence that interhel ...... in to the fusion-active state.
@nl
P2093
P2860
P1433
P1476
Genetic evidence that interhel ...... in to the fusion-active state.
@en
P2093
Jack H Nunberg
Kathryn E Follis
Scott J Larson
P2860
P304
P356
10.1128/JVI.76.14.7356-7362.2002
P407
P577
2002-07-01T00:00:00Z